Publication date: Jul 16, 2024
To synthesize the clinical experience of patients with COVID-19-associated acute respiratory distress syndrome (ARDS) or pulmonary fibrosis (PF) receiving lung transplantation (LTx) and compare the characteristics and outcomes of COVID-19 and non-COVID-19 LTx patients. A literature search of online databases (PubMed, Web of Science, Embase, the Cochrane Library, China Science and Technology Journal Database, and Wan Fang databases) was performed regarding LTx for COVID-19-associated ARDS or PF. This study was registered on PROSPERO (CRD2024507647). Eight eligible studies were included with 478 COVID-19 LTx patients and 163 non-COVID-19 LTx patients. In COVID-19 LTx patients, the pooled hospital mortality and follow-up survival rate was 0. 00% (95%CI 0. 00-0. 03) and 87. 40% (95%CI 0. 76-0. 96). Compared to non-COVID-19 LTx patients, COVID-19 LTx patients were associated with significantly higher rate of primary graft dysfunction (odds ratio [OR] 8. 72, 95%CI 3. 54-21. 47, P < 0. 001) but significantly higher follow-up survival rate (OR 2. 48, 95%CI 1. 02-6. 01, P = 0. 04), within an overall similar follow-up period. For patients with COVID-19-associated ARDS or PF, LTx offers acceptable short-term outcomes and is suggested as a viable lifesaving treatment.
| Concepts | Keywords |
|---|---|
| China | COVID-19 |
| Crd2024507647 | lung transplant |
| Fibrosis | meta-analysis |
| Library | pulmonary fibrosis |
| Lifesaving |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | infection |
| disease | MESH | acute respiratory distress syndrome |
| disease | MESH | pulmonary fibrosis |
| disease | MESH | primary graft dysfunction |
| disease | VO | viable |
| disease | MESH | Long Covid |